Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 iptacopan in C3 glomerulopathy
2020-004589-21Phase 3Active
- Sponsor
- Novartis
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Complement 3 glomerulopathy (C3G) comparing iptacopan with placebo (2 arms). Primary endpoint: Primary endpoint for adult participants. Started Apr 2021; status: active.
02
Drugs
Iptacopan
03
Conditions
Complement 3 glomerulopathy (C3G)
Beyond the preview
Go deeper on 2020-004589-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004589-21.